Isomorphic Labs and MSD Partner on AI-Driven Cancer Drug Discovery
Isomorphic Labs and MSD have agreed to collaborate on discovering small-molecule drug candidates for a strategically important cancer indication. The partnership combines Isomorphic Labs’ AI drug design platform with MSD’s proprietary data and drug discovery expertise.
- Isomorphic Labs and MSD will discover small-molecule candidates for a cancer indication.
- Isomorphic Labs will use its IsoDDE platform for computational predictions and molecular design.
- MSD will lead preclinical and clinical development, manufacturing and commercialization.
- The agreement includes upfront, milestone and tiered royalty payments for Isomorphic Labs.
- Isomorphic Labs can cofund development activities for higher royalties.
AI design meets pharmaceutical development
Under the agreement, Isomorphic Labs will carry out in silico predictions and provide molecular designs using its proprietary IsoDDE drug design engine. The platform will incorporate high-quality proprietary datasets selected and supplied by MSD for the collaboration.
MSD will take responsibility for preclinical and clinical development, manufacturing and commercialization of products resulting from the partnership. The announcement does not identify the cancer indication or provide a timeline for research, development or potential commercialization.
Milestone payments and an option to cofund development
Isomorphic Labs will receive an upfront payment from MSD. It may also receive payments tied to specified research, development, regulatory and commercial milestones, along with tiered royalties on net sales.
The agreement gives Isomorphic Labs an option to cofund development activities in exchange for higher royalties. The announcement does not disclose the value of the upfront payment, the milestone payments or the royalty rates.
Sarah Skerratt, Isomorphic Labs’ research director, said the companies would apply the company’s drug design platform to make progress in discovery and described the partnership as a shared effort to address unmet patient needs. George Addona, senior vice president and head of discovery, preclinical development and translational medicine at MSD Research Laboratories, said close coordination between wet-lab and dry-lab functions is central to using AI and machine learning in molecular invention.
What the partnership means for AI drug discovery
The collaboration gives Isomorphic Labs a role focused on computational prediction and molecule design, while MSD leads the later stages needed to test, manufacture and commercialize any resulting products. It therefore links an AI-led discovery workflow with the data resources and pharmaceutical development capabilities of an established biopharmaceutical company.
Isomorphic Labs was founded in 2021 and is led by chief executive Sir Demis Hassabis and president Max Jaderberg. The company says IsoDDE consists of foundational AI models and is designed to support drug design across different modalities. It is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
The companies have presented the arrangement as a way to explore complex biology and identify drug candidates more quickly. However, MSD’s announcement cautions that candidates in development may not receive regulatory approval or achieve commercial success. The partnership is therefore an early research collaboration, rather than a confirmation that a cancer medicine will reach patients.
